21:30 GMT +319 November 2019
Listen Live
    Indian employees of the country's third-biggest drugs company Sun Pharma walk outside its research and development centre in Mumbai. (File)

    India's Biggest Pharmaceutical Company Enters Russian, CIS Markets

    © AFP 2019 / INDRANIL MUKHERJEE
    Asia & Pacific
    Get short URL
    1108
    Subscribe

    Out of the total deal value, $ 24 million will be given for acquiring 85.1 percent equity stake in the Russian firm. The Indian company will also assume Biosintez’s debt of $ 36 million.

    New Delhi (Sputnik): India's biggest drug maker, Sun Pharmaceuticals is set to enter the Russian and CIS market. The company has signed an agreement with Russia’s Biosintez for acquiring its majority stake for about $ 60 million. The transaction, expected to be completed by the year-end, is subject to approval by the Russian Federal Anti-Monopoly Service and other contract conditions.

    "This transaction gives us access to local manufacturing capability across multiple dosage forms in Russia, enabling us to serve its pharmaceutical market more effectively," Aalok Shanghvi, head of Emerging Markets of Sun Pharma, said in a statement.

    Biosintez recorded a turnover of $ 52 million in 2015. It basically caters to the hospital segment with a facility in Penza region to manufacture a variety of dosage forms.

    The Russian pharmaceutical market is pegged at about $10 billion, growing at 7.4 percent in local currency terms. Indian companies have been knocking at the doors for several years.

    Sun Pharma’s strategy over the past two decades is to grow with acquisitions. This approach has made it the world’s fifth-largest specialty generic pharmaceutical company. It made its first overseas acquisition by acquiring the US-based Caraco Pharma in 1997 and has since then been on the lookout for takeovers mainly in the US and Australia.

    Sun Pharma’s net profit surged 117.25 percent in the second quarter of the current financial year compared to the same period last year.

    Related:

    Time to Wake Up: China May End India's Drug Trade Dominance
    India in Talks for Export of Light Combat Aircraft (LCA) Tejas
    India to Export Home Made Advanced Sonar System for Small Naval Platforms
    Tags:
    pharmaceutics, CIS, Russian Federal Anti-Monopoly Service (FAS), India
    Community standardsDiscussion
    Comment via FacebookComment via Sputnik